Part-Time
Site Research Assistant
Condord
IQVIA
10,001+ employees
Analytics and research for life sciences
No salary listed
Mid
Sydney NSW, Australia
In Person
- BS/BA in life sciences or educational equivalent and/or relevant work experience in a clinical environment or medical setting, e.g. clinical research coordinator, Research Assistant, nurse, medical assistant, other medical profession
- Good knowledge of clinical trials, combined with in-depth knowledge of departmental, protocol and study-specific operating procedures, consent forms, and study schedules
- Must have at least 2 years experience working as a Clinical Research Assistant or Clinical Research Coordinator at a clinical trial site
- Basic knowledge of medical terminology
- Strong IT competence, skilled in using MS Windows and Office applications such as Access, Outlook, Excel, and Word
- Excellent interpersonal skills with the ability to establish and maintain effective working relationships with co-workers, managers and clients
- Good organizational skills with the ability to pay close attention to detail
- Maintaining up-to-date study protocols, case report forms (CRFs), Electronic Data Capture (EDC) systems, and other study documents
- Support with screening and enrolment of patients and collection of related documents (informed consent, privacy consent, etc.)
- Planning and coordinating logistical activity for study procedures according to the study protocol
- Data entry, data quality checking, and query resolution to ensure adherence to study protocol and quality control for content accuracy and completeness
- Management and shipment of biological samples
- Performing ECG, taking vital signs, phlebotomy
- Coordinating with study monitor on study issues and effectively responding to monitor-initiated questions
- Administrative research task
IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main product, IQVIA Connected Intelligence™, utilizes large datasets and technology to offer quick insights that help clients speed up the development and marketing of new medical treatments. This service is designed to assist various healthcare stakeholders, including biotech and pharmaceutical companies, in understanding diseases and improving healthcare outcomes. A key aspect that sets IQVIA apart from its competitors is its strong focus on patient privacy, employing advanced technologies to protect individual data. The company's goal is to enhance the healthcare landscape by facilitating the discovery of cures and improving patient care.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Simplify's Take
What believers are saying
- IQVIA leads in decentralized clinical trial technologies, enhancing market position.
- The Med-R1 8B LLM launch boosts clinical data interpretation capabilities.
- Recognition for patient engagement app highlights digital health tool importance.
What critics are saying
- Healthcare industry's profit-driven model scrutiny may increase regulatory pressures.
- Access disparities in CAR T-cell therapy could hinder market penetration.
- Reliance on senior notes for financing exposes IQVIA to financial risks.
What makes IQVIA unique
- IQVIA's Connected Intelligence™ offers unique insights across healthcare sectors.
- The company excels in patient privacy with advanced privacy-enhancing technologies.
- IQVIA's Med-R1 8B LLM outperforms larger models in medical reasoning.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Company News
IQVIA wins the Fierce CRO Award for Innovative Approaches to Patient-Centric Research.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in...
<p> <strong>RESEARCH TRIANGLE PARK, N.C.</strong> – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”). </p> <p> The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer’s revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. </p> <p> This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. </p> <br /> <h5> About IQVIA </h5> <p> IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. </p> <p> IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. </p> <br /> <h5> Forward Looking Statements </h5> <p> Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially. </p> <br /> <h5> IQVIAFIN </h5> <p> Kerri Joseph, IQVIA Investor Relations (<a href="mailto:[email protected]">[email protected]</a>)<br /> +1.973-541-3558 </p>
Research Triangle Park, N.C., - June 16, 2025 - IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program.
New National Campaign Confronts the Healthcare Industry's Perverse Incentives and Sparks a Movement for Preventive WellnessNEW YORK, May 19, 2025 /PRNewswire/ -- Vimergy, the premium supplement company helping people reclaim their health with pure, potent, and timeless products, today launched the "Mouth of America" – an immersive national campaign debuting a large-scale art installation in New York City. Designed to provoke and inspire, the campaign calls attention to America's real health crisis: chronic, system-driven illness fueled by a healthcare model that profits when we stay sick. This problem shows no sign of abating: In 2024, Americans collectively took 215 billion doses of prescription medication